Compare Truist Financial Corporation Common Stock (TFC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Truist Financial (TFC) trades at $45.92, down 1.54% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the bank maintains solid profitability with 28.01% net income margin and attractive valuation at 10.56 P/E ratio. Recent earnings show beats in Q1 and Q2 2026, while Q3 results are pending. The company is executing strategic portfolio optimization including a $5.5B auto loan sale under new CEO Michael Lyons.

TFC presents a value opportunity with 17.6% upside to consensus price target of $54, supported by 50% analyst buy ratings. Key catalysts include Q3 earnings release on October 16 and ongoing business simplification. Risks include near-term net interest margin pressure and frozen dividend since 2022. The stock offers income investors a compelling risk-reward profile with improving credit quality and capital optimization initiatives.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.